RxDoctor Payments Data

Suzanne Burge, MD

Family Medicine · du Quoin, ILNPI 1467456798

Payments from drug & device makers

$14,984in general payments, 2019–2025

Across 976 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$14,945100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,984 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$23,130
Medicare patients
181
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$83,905
OzempicSemaglutide69$77,469
MounjaroTirzepatide63$75,233
EliquisApixaban79$59,553
TrulicityDulaglutide52$58,621
MyrbetriqMirabegron46$35,647
LinzessLinaclotide42$34,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,624
FarxigaDapagliflozin Propanediol36$23,939
Aimovig AutoinjectorErenumab-Aooe23$16,286
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$12,595
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$12,006
GemtesaVibegron17$11,261
XareltoRivaroxaban18$9,991
Icosapent Ethyl23$7,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,951$133,854115 claims
Boehringer IngelheimJardiance$1,113$83,90585 claims
Novo NordiskOzempic$1,155$77,46969 claims
PfizerEliquis$1,058$59,55379 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,367$45,52465 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,023$35,94648 claims
Astellas Pharma US IncMyrbetriq$193$35,64746 claims
AbbVieLinzess$1,468$34,45642 claims
Sumitomo Pharma America, Inc.Gemtesa$176$11,26117 claims
Johnson & JohnsonXarelto$99$9,99118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in du Quoin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →